Medical Developments International Ltd
ASX:MVP
Net Margin
Medical Developments International Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Medical Developments International Ltd
ASX:MVP
|
63.7m AUD |
-78%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
729.1B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.3B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.6B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
201.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.6B USD |
13%
|
Medical Developments International Ltd
Glance View
Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The company is headquartered in Melbourne, Victoria and currently employs 68 full-time employees. The company went IPO on 2003-12-15. The firm is focused on manufacturing and distributing pharmaceutical drugs, and medical and veterinary equipment. The firm operates through three segments: Pharmaceuticals, Medical Devices and Veterinary Products. The Pharmaceuticals segment is engaged in the sale of Penthrox primarily within Australia, New Zealand, Europe and the United Kingdom, and some sales in the Middle East, Asia and South Africa. The Medical Devices segment is engaged in the sale of medical devices, particularly the Space Chamber and Breath-Alert PeakFlow meters, primarily within Australia, the United Kingdom/Europe, North America, and some sales in Asia and New Zealand. The Veterinary Products segment is engaged in the sale of veterinary products within Australia, Europe, and Asia.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Medical Developments International Ltd's most recent financial statements, the company has Net Margin of -78.2%.
You don't have any saved screeners yet